Assessment of the Risk for Developing Radiation Pneumonitis Caused by Paclitaxel-based Chemotherapy plus Radiotherapy in Breast Cancer Patients

庞青松,宋勇春,王军,张柏林,王平
DOI: https://doi.org/10.3969/j.issn.1000-8179.2007.05.009
2007-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: To assess the risk of radiation pneumonitis caused by paclitaxel-based chemotherapy plus radiotherapy in breast cancer patients. Methods: The incidence of radiation pneumonitis in 276 breast cancer patients receiving chemotherapy plus radiotherapy was retrospectively analyzed. Of the 276 patients, 215 were treated postoperatively with three fields of radiotherapy and 61 were treated with whole-breast tangent radiotherapy following breast-conserving surgery. Based on various chemotherapeutic regimens, the patients were divided into 3 groups: the PA (Paclitaxel and Adriamycin) group, CAF (Cyclophosphamide, Adriamycin, Fluorouracil) group and CMF (Cyclophosphamide, MTX, Fluorouracil) group. The rate of radiation pneumonitis in these groups was compared. Results: The risks for developing radiation pneumonitis in the PA group are higher than in the other two groups. There is no significant difference between the other two groups. Conclusion: Paclitaxel-based chemotherapy increases the risk of radiation pneumonitis in breast cancer patients. © 1994-2011 China Academic Journal Electronic Publishing House. All rights reserved.
What problem does this paper attempt to address?